No, Acamprosate is NOT a Medication for Stimulant Use Disorder
Acamprosate is FDA-approved exclusively for alcohol use disorder (AUD) and has no established role in treating stimulant use disorders. The medication works by modulating glutamate and GABA neurotransmitter systems to restore neuronal balance disrupted by chronic alcohol exposure, not stimulant use 1.
Evidence Base
FDA-Approved Indication
The FDA drug label clearly establishes acamprosate's mechanism as specific to alcohol dependence. The medication "reduces alcohol intake in alcohol-dependent animals in a dose-dependent manner and this effect appears to be specific to alcohol and the mechanisms of alcohol dependence" 1. There is no FDA approval or indication for stimulant use disorders.
Failed Clinical Trial in Cocaine Dependence
A double-blind, placebo-controlled trial directly tested acamprosate for cocaine dependence and found it completely ineffective 2. In this 60-patient study:
- No difference in cocaine-positive urine screens between acamprosate and placebo
- No reduction in cocaine craving
- No improvement in cocaine withdrawal symptoms
- No benefit on any addiction severity measures
The investigators concluded that "acamprosate does not appear to be a promising medication for the treatment of cocaine dependence" 2.
Current Treatment Context
The 2020 JAMA Network Open systematic review examining pharmacotherapy for substance use disorders included studies on alcohol (50%), cocaine (23%), and opioids (20%) 3. Notably, acamprosate was used in 42% of effect sizes, but exclusively in the alcohol use disorder studies, not the stimulant studies. This reflects the lack of evidence supporting its use for stimulants.
Clinical Pitfalls to Avoid
- Do not extrapolate from alcohol use disorder efficacy: While acamprosate modulates glutamatergic pathways, this mechanism has not translated to benefit in stimulant use disorders
- Recognize the absence of FDA-approved pharmacotherapy for stimulant use disorders: Unlike AUD, there are no FDA-approved medications for cocaine or methamphetamine use disorders, making behavioral interventions the principal approach 3
- One case report exists for inhalant use disorder with comorbid AUD, but this represents anecdotal evidence only and involved a patient already on disulfiram for alcohol 4
What to Use Instead
For stimulant use disorders, evidence-based treatment consists of:
- Behavioral interventions as first-line: Cognitive behavioral therapy, contingency management, or motivational enhancement therapy 3
- Acute overamping management: Benzodiazepines followed by antipsychotics if needed, with behavioral de-escalation 5
- No established pharmacotherapy: Research continues, but no medications have demonstrated efficacy comparable to those available for AUD or opioid use disorder